This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Depression  • Adverse Effects  • Alert me on articles by topic

Mike Mitka

JAMA. 2003;290:2534.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The US Food and Drug Administration (FDA) has issued an alert about a possible link between antidepressant drug treatment for pediatric patients with major depressive disorder (MDD) and increased prevalence of suicidal thinking and suicide attempts.

In an October 27 "Public Health Advisory," the FDA notified physicians about preliminary data from a review of studies suggesting an excess of reported suicidal ideation and suicide attempts for pediatric patients receiving certain antidepressant drugs in clinical trials compared with those assigned to placebo. The FDA has completed a preliminary review of 20 placebo-controlled studies involving more than 4100 pediatric patients for eight antidepressant drugs (citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, and venlafaxine) studied under the "pediatric exclusivity provision" of the FDA Modernization Act. The provision provides marketing incentives—6 months of exclusive sales—to manufacturers who conduct studies of drugs in children.

The FDA stressed that in these 20 studies, there . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bias in Clinical Intervention Research
Gluud
Am J Epidemiol 2006;163:493-501.
ABSTRACT | FULL TEXT  

Suicide Risk During Antidepressant Treatment
Simon et al.
Am. J. Psychiatry 2006;163:41-47.
ABSTRACT | FULL TEXT